Table 2.

Long term effects of SGLT2 inhibitors as approved glucose-lowering agents.

Inhibitor	Diabetes	Effects	References
Canagliflozin	Type 2	Reduces GFR, HbA1C, BW, BP, FPG.	[266, 267]
Dapagliflozin	Type 2	Reduces GFR, BP, BW, HbA1C, albumin and stabilizes insulin dosing.	[268–272]
Empagliflozin	Type 1 Type 2	Reduces GFR, plasma NO, HbA1C, arterial stiffness, heart failure hospitalization, cardiovascular death.	[207, 273–275]
Ipragliflozin	Type 2	Reduces HbA1C, BW, FPG and improves liver function and lipid profile.	[276–278]

Glycated haemoglobin, HbA_1C, glomerular filtration rate, GFR, fasting plasma glucose, FPG, body weight, BW, blood pressure, BP, and nitric oxide, NO.